Zobrazeno 1 - 10
of 281
pro vyhledávání: '"M. Ziller"'
Autor:
A. Nörenberg, Krisztina Juhasz, Niels Fertig, M. Ziller, T Johannssen, Ulrich Thomas, F. Alves, O. Reinhardt, Elena Dragicevic, Sonja Stölzle-Feix
Publikováno v:
Toxicology Letters. 350:S100-S101
Publikováno v:
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 48:S29-S29
Background: Pyomyositis is an infectious disease usually encountered in tropical regions. It typically occurs in immunocompromised hosts and most commonly affects lower limb muscles. Our patient was a healthy Canadian with an atypical presentation of
Publikováno v:
Journal of Obstetrics and Gynaecology Research. 40:1592-1597
Aim Adequate blood glucose control during pregnancy is important because gestational diabetes mellitus (GDM) is known to have adverse effects on the mother and child. Due to an increasing prevalence of GDM in recent years, more information on the use
Autor:
Peter H. Kann, Monika Baier, Annette Kauka, Mathias Muth, Peyman Hadji, M. Ziller, Katrin Birkholz
Publikováno v:
Breast Cancer Research and Treatment. 144:343-351
Endocrine therapy (ET) is a key treatment modality in hormone receptor positive (HR+) early breast cancer (BC) patients. Although the anticancer activity of adjuvant ET + zoledronic acid (ZOL) has been investigated, the potential effects of ET ± ZOL
Autor:
Mathias Muth, Peyman Hadji, M. Ziller, Martina Bauer, Monika Baier, Katrin Birkholz, Anette Kauka
Publikováno v:
Osteoporosis International. 25:1369-1378
The effects of bisphosphonates on altered bone turnover marker (BTM) levels associated with adjuvant endocrine or chemotherapy in early breast cancer have not been systematically investigated. In ProBONE II, zoledronic acid decreased these elevated B
Publikováno v:
Geburtshilfe und Frauenheilkunde. 76
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cancer Research. 71:P2-17
Background Previous studies have suggested a correlation between the occurrence of vasomotor or joint symptoms during tamoxifen or aromatase inhibitor treatment and improved clinical response. We assessed if there was any correlation between treatmen
Autor:
U.-S. Albert, M Baier, T Bauer, Matthias Kalder, P. Hadji, Mathias Muth, K Birkholz, A Kauka, M. Ziller
Publikováno v:
Cancer Research. 71:P2-19
Background: Based on baseline bone mineral density (BMD), adjuvant chemotherapy or endocrine therapy for early breast cancer patients can lead to substantially increased fracture risk. A significant decrease of BMD >10% after 2 years of chemotherapy
Autor:
Lina Asmar, Stephen E. Jones, J.G.H. van Nes, Annette Hasenburg, C. Van der Velde, J. Kuck, M. Ziller, P. Hadji, T. Menschik, H Nortier
Publikováno v:
Cancer Research. 70:P5-11
Background: TEAM is the largest AI phase III trial comparing exemestane with tamoxifen followed by exemestane as adjuvant breast cancer therapy in postmenopausal women. We performed a meta-analysis of three randomized sub-studies of the TEAM trial co